- Home
- SEVN vs STXS Comparison
SEVN vs STXS Comparison
Compare SEVN & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- STXS
- Stock Information
- Founded
- SEVN 1986
- STXS 1990
- Country
- SEVN United States
- STXS United States
- Employees
- SEVN N/A
- STXS N/A
- Industry
- SEVN Real Estate Investment Trusts
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SEVN Real Estate
- STXS Health Care
- Exchange
- SEVN Nasdaq
- STXS Nasdaq
- Market Cap
- SEVN 188.3M
- STXS 151.3M
- IPO Year
- SEVN N/A
- STXS 2004
- Fundamental
- Price
- SEVN $11.70
- STXS $1.85
- Analyst Decision
- SEVN Strong Buy
- STXS
- Analyst Count
- SEVN 4
- STXS 0
- Target Price
- SEVN $14.50
- STXS N/A
- AVG Volume (30 Days)
- SEVN 57.0K
- STXS 471.9K
- Earning Date
- SEVN 04-28-2025
- STXS 05-12-2025
- Dividend Yield
- SEVN 11.62%
- STXS N/A
- EPS Growth
- SEVN N/A
- STXS N/A
- EPS
- SEVN 1.20
- STXS N/A
- Revenue
- SEVN $29,847,000.00
- STXS $26,918,000.00
- Revenue This Year
- SEVN $14.73
- STXS $34.90
- Revenue Next Year
- SEVN $5.39
- STXS $58.64
- P/E Ratio
- SEVN $10.05
- STXS N/A
- Revenue Growth
- SEVN N/A
- STXS 0.55
- 52 Week Low
- SEVN $10.18
- STXS $1.54
- 52 Week High
- SEVN $14.66
- STXS $2.72
- Technical
- Relative Strength Index (RSI)
- SEVN 45.15
- STXS 52.25
- Support Level
- SEVN $10.61
- STXS $1.78
- Resistance Level
- SEVN $12.16
- STXS $1.86
- Average True Range (ATR)
- SEVN 0.72
- STXS 0.12
- MACD
- SEVN 0.04
- STXS 0.03
- Stochastic Oscillator
- SEVN 53.52
- STXS 92.42
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.